Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 30, 2022
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
[ Wed, Mar 30th 2022
] - WOPRAI
Michael King Maintained (VINC) at Strong Buy with Increased Target to $28 on, Mar 30th, 2022
Michael King of HC Wainwright & Co., Maintained "Vincerx Pharma, Inc." (VINC) at Strong Buy with Increased Target from $25 to $28 on, Mar 30th, 2022.
Michael has made no other calls on VINC in the last 4 months.
There is 1 other peer that has a rating on VINC. Out of the 1 peers that are also analyzing VINC, 0 agree with Michael's Rating of Hold.
This is the rating of the analyst that currently disagrees with Michael
- Li Watsek of "Cantor Fitzgerald" Initiated at Buy and Held Target at $25 on, Thursday, December 23rd, 2021
